AGIOS PHARMACEUTICALS, INC.: operating_income
| Value | {"amount": -335916000, "concept": "us-gaap:OperatingIncomeLoss", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-12-31 |
| Status | current |
| Entity | AGIOS PHARMACEUTICALS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T14:11:29.585785+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/cd1b624e-d79e-453a-964c-1ea43b76fb2d
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001439222-22-000024Retrieved: 2026-08-19T14:11:29.585785+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001439222/operating-income/2020-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/cd1b624e-d79e-453a-964c-1ea43b76fb2d
History
- supersedes {"amount": -316149000, "concept": "us-gaap:OperatingIncomeLoss", "currency": "USD"} (evidence 0001439222-21-000029)